Jason A. Dubovsky, Ph.D.
Affiliations: | 2011 | Biology (Cell Biology, Microbiology, Molecular Biology) | University of South Florida, Tampa, FL, United States |
Area:
Cell Biology, Immunology, Molecular BiologyGoogle:
"Jason Dubovsky"Parents
Sign in to add mentorJavier A. Pinilla-Ibarz | grad student | 2011 | University of South Florida | |
(Epigenetic Modifiers to Augment the Immunogenicity of Chronic Lymphocytic Leukemia.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Reiss DJ, Do T, Kuo D, et al. (2019) Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response Blood. 134: 202-202 |
Kumar A, Vardhana S, Moskowitz AJ, et al. (2018) Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma. Blood Advances. 2: 871-876 |
Siddiqi T, Soumerai JD, Wierda WG, et al. (2018) Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib Blood. 132: 300-300 |
Cutler C, Jaglowski S, Arora M, et al. (2018) Ibrutinib for Chronic Graft-Versus-Host Disease: A Safety and Pharmacokinetic Analysis in Patients Treated with Concomitant Antifungal CYP3A Inhibitors or Immunosuppressants Biology of Blood and Marrow Transplantation. 24: S186-S187 |
Sahaf B, Tebaykin D, Hopper M, et al. (2018) Ibrutinib-Mediated Inhibition of cGVHD Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells Biology of Blood and Marrow Transplantation. 24: S20-S21 |
Miklos D, Cutler CS, Arora M, et al. (2017) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood |
Miklos DB, Jagasia MH, Greinix H, et al. (2017) A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease. Journal of Clinical Oncology. 35: TPS7072-TPS7072 |
Solman I, You H, Taylor M, et al. (2017) Ibrutinib vs chlorambucil: Immunophenotypic and quantitative impacts on circulating immune cells in chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 35: 7524-7524 |
Sahaf B, Tebaykin D, Hopper M, et al. (2017) Ibrutinib Inhibits cGVHD Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells Blood. 130: 4481-4481 |
Natarajan G, Terrazas C, Oghumu S, et al. (2016) Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. Oncoimmunology. 5: e1057385 |